Neuronal nicotinic acetylcholine receptor subunit alpha-2 (CHRNA2)

The Neuronal nicotinic acetylcholine receptor subunit alpha-2 (CHRNA2) is a critical component of heteromeric nicotinic receptors (nAChRs) in the central nervous system, where it typically assembles with beta subunits like beta-2 or beta-4 to form functional pentameric ligand-gated ion channels. These receptors mediate fast synaptic transmission and modulate the release of various neurotransmitters, playing a significant role in cognitive functions, reward pathways, and the regulation of sleep-wake cycles. CHRNA2 is particularly noted for its expression in the cerebral cortex and thalamus, and mutations in the CHRNA2 gene have been linked to autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). In drug development, CHRNA2 is a target of interest for treating nicotine addiction and cognitive deficits, as its modulation can influence the brain's cholinergic signaling. However, therapeutic targeting is challenged by the need for subtype selectivity to avoid adverse effects associated with the widespread distribution of other nicotinic receptor isoforms.

Other names

Cholinergic receptor nicotinic alpha 2 subunitnAChR alpha-2Acetylcholine receptor subunit alpha-2CHRNA2

Agonism (opening the ion channel to allow cation influx), Antagonism (blocking the channel or binding site), and Positive Allosteric Modulation (enhancing channel response to acetylcholine).